Your science is strong. But buyers don’t trust the category.
The science may be solid, but buyers lump you in with the noise. Skepticism is the default, earned by everything the category has overpromised. Until you prove otherwise, you get priced like the rest.
Science is evolving and evidence standards vary across the category
Buyers have been burned by overpromising. Skepticism is the default starting position.
The category attracts attention faster than it builds trust
Differentiation requires more than strong data in a market saturated with bold claims
Clinical credibility alone doesn’t protect you from category-wide skepticism
If any of this is true, you have a credibility gap:
Buyers are genuinely interested but hesitant to commit
Your science is hard to translate commercially without oversimplifying it
You’re competing for credibility against companies making claims you won’t make
Growth exists but lacks the confidence that attracts serious investors
Where growth breaks
Longevity carries a credibility tax. Every company in the category pays it regardless of science quality. Buyers have seen enough overpromising that skepticism is built into how they evaluate everything — including companies doing genuinely rigorous work.
Most respond by oversimplifying or amplifying. Both backfire. Flattening the science undermines your credibility. Bigger claims accelerate the skepticism you’re trying to overcome.
Attention without trust doesn’t convert. High attention combined with low trust is a dangerous position going into a fundraise or exit.
What buyers are really evaluating
Is the science credible and independently defensible?
Are claims ones that will hold up under investor and regulatory scrutiny?
Is this serious science or category noise with better branding?
What’s the evidence this works at scale, not just in controlled conditions?
Will this hold up if the evidence base continues to evolve?
High attention. Low trust.
That’s the risk when scientific strength isn’t insulated from the skepticism the category has earned.
How we help: Speed. Clarity. Impact.
We’ve worked with science-driven companies navigating the gap between strong evidence and commercial credibility.
Our work lets serious companies stand apart from the noise without diluting what makes the science real.
Clarify positioning without oversimplifying
Translate complex science into a defensible commercial narrative that holds up under investor scrutiny, without flattening the nuance that gives your work credibility.
Build proof that reduces skepticism
Structure evidence to directly counter the doubts buyers bring into the room. Proof is more effective when it anticipates objections.
Align growth with credibility
Ensure your brand, GTM, and leadership narrative consistently reinforce trust, so every touchpoint reduces risk perception instead of adding to it.
Why Legacy DNA
We translate complex science into commercial clarity — not simplified marketing.
We’re built around how investors and acquirers evaluate credibility risk in emerging categories.
We’ve guided multiple healthcare companies through exit, including ones navigating category-level skepticism.
Senior-led throughout. We don’t delegate the work that matters.
Axium Growth Story
A science-driven company where structured proof and clearer positioning increased investor confidence and accelerated traction.
Longevity companies moving from early traction to enterprise scale
Science-driven organizations where commercial positioning hasn’t kept pace with the evidence
Leadership teams facing investor skepticism despite strong underlying data
Companies preparing for diligence where claims need to hold up independently
Not a fit
Early-stage concepts without validated science
Companies relying on hype-driven positioning
Teams unwilling to align claims with independently defensible proof
Find out where your business is being discounted
In 30 minutes, we’ll show you exactly where skepticism is entering your growth story and where clarity could change the outcome. We’ll identify where your narrative creates doubt, surface the credibility gap most likely to appear in diligence, and show you where alignment could strengthen your positioning.
Why is it hard to scale a longevity company despite strong market interest?
Interest isn’t the same as trust. Buyers evaluate longevity companies through a skepticism-first lens because of how much the category has overpromised. Without a credible narrative that reduces perceived risk, interest doesn’t convert into growth.
What do investors look for in longevity companies?
Credible science, defensible claims, and a growth model built on evidence rather than category hype. Companies that actively reduce perceived risk earn stronger valuations.
How do you differentiate in a crowded longevity market?
Not by making bigger claims. The companies that stand out explain their value clearly, support it with evidence that anticipates objections, and maintain credibility consistently across every channel.
How do you communicate complex science without losing credibility?
By translating, not simplifying. The goal is accessibility without sacrificing integrity — built around how buyers evaluate risk, not how scientists communicate findings.
When should a longevity company invest in commercialization strategy?
As soon as you move beyond early traction. Building credibility infrastructure early makes it easier to convert interest into growth and walk into a fundraise without the category working against you.
